Evidence map›Paper›PMID 40671492›Full record

ArticleHaematologica2026

Changing donors improves outcomes of second transplantation in patients who experienced graft failure after first allogeneic stem cell transplantation.

Rui Ma, Xiao-Yu Zhu, Yue Lu, Jia Chen, Li Xuan, Hai-Long Yuan, Yang Cao, Wei-Jie Cao, Xiao-Sheng Fang, Kou-Rong Miao and 14 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Rui MaPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Xiao-Yu ZhuDepartment of Hematology, the First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei.
Yue LuBeijing Lu Daopei Hospital, Beijing.
Jia ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou.
Li XuanDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou.
Hai-Long YuanThe First Affiliated Hospital of Xinjiang Medical University, Urumqi.
Yang CaoDepartment of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan.
Wei-Jie CaoDepartment of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou.
Xiao-Sheng FangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan.
Kou-Rong MiaoPeople's Hospital of Jiangsu Province, Suzhou.
Xiao-Xia HuRuijin Hospital, Shanghai.
Hai YiDepartment of Hematology, The General Hospital of Western Theater Command, Chengdu.
Yan-Min ZhaoBone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou.
Yuan-Bin WuGuangdong Hospital of Traditional Chinese Medicine, Guangzhou.
Ting YangDepartment of Hematology, The First Affiliated Hospital, Fujian Medical University, Fuzhou.
Hong-Tao WangDepartment of Hematology, Shengjing Hospital of China Medical University, Shenyang.
Yue YinPeking University First Hospital, Beijing.
Zhong-Ming ZhangDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Lan-Ping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Kai-Yan LiuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, P.R. China; Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing. huangxiaojun@bjmu.edu.cn.
Yu-Qian SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing. sunyuqian83@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A second transplantation is almost the only salvage for patients encountering graft failure (GF) following first allogeneic stem cell transplantation. However, there were no standard protocols for second transplantations, and the role of changing donors remained controversial. We retrospectively studied 272 consecutive patients from 18 Chinese centers undergoing second transplantations due to GF, aiming to assess the impact of changing donors and the factors affecting second transplantation outcomes. The primary endpoint was neutrophil engraftment. Other endpoints included platelet engraftment, graft-versushost disease (GvHD), transplant-related mortality (TRM), relapse, and survival. Of the 272 patients, 193 (71.0%) patients experienced primary GF, and 70.6% (192) used a different second donor. Neutrophil engraftment was achieved in 218 (86.3%) patients by day (d)28, and platelet engraftment was achieved in 164 (70.0%) patients by d100. The 3-year cumulative incidence of acute GvHD, chronic GvHD, relapse, and TRM were 43.5%, 27.8%, 15.6%, and 44.6%, respectively. The 1-year and 3-year overall survival (OS) were 56.1% and 49.5%, respectively. Compared to using the same donor, changing donors significantly improved neutrophil engraftment (92.4% vs. 71.4%, P<0.001) and platelet engraftment (76.9% vs. 51.8%, P<0.001), 1-year TRM (34.8% vs. 56.3%, P<0.001), and OS (61.9% vs. 42.7%, P<0.001). Subgroup analysis confirmed engraftment benefit of changing donor in primary GF (P<0.001), but not in secondary GF (P=0.346). This is the largest multicenter study of second transplantations for GF, suggesting that changing donors might be critical for engraftment and survival after second transplantation.

Indexed as

Graft RejectionHematopoietic Stem Cell TransplantationTissue DonorsAdolescentAdultAgedChildFemaleGraft vs Host DiseaseHumansMaleMiddle AgedRetrospective StudiesTransplantation, HomologousTreatment OutcomeYoung Adult

Identifiers

PMID40671492
PMCPMC12862326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.